Dynavax Technologies | DVAX - Pre Tax Profit

Stock Price
15.50
Daily Change
0.01 0.06%
Monthly
0.58%
Yearly
17.87%
Q1 Forecast
15.01

Dynavax Technologies reported $28.42M in Pre-Tax Profit for its fiscal quarter ending in September of 2025.





Pre Tax Profit Change Date
AbbVie USD 4.38B 1.92B Sep/2025
Adma Biologics USD 47.52M 7.42M Sep/2025
Amgen USD 3.92B 2.35B Sep/2025
AstraZeneca USD 3.24B 117M Sep/2025
Biogen USD 557.3M 186.7M Sep/2025
BioMarin Pharmaceutical USD -26.32M 324.19M Sep/2025
Bristol-Myers Squibb USD 3.11B 1.34B Sep/2025
Dynavax Technologies USD 28.42M 7.2M Sep/2025
Gilead Sciences USD 2.43B 780M Jun/2025
Glaxosmithkline GBP 2.46B 569M Sep/2025
Merck USD 6.74B 22M Sep/2025
Neurocrine Biosciences USD 291.8M 132.3M Sep/2025
Novartis USD 4.2B 335M Sep/2025
Pfizer USD 3.33B 290M Sep/2025
Regeneron Pharmaceuticals USD 1.76B 244.6M Sep/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sarepta Therapeutics USD -194.05M 347.69M Sep/2025
TG Therapeutics USD 25.91M 5.01M Sep/2025
Vertex Pharmaceuticals USD 1.3B 15.8M Sep/2025